Pioglitazone attenuates cardiac fibrosis and hypertrophy in a rat model of diabetic nephropathy

Journal of Cardiovascular Pharmacology and Therapeutics

Volumn 17, Issue 3, 2012, Pages 324-333

  Elrashidy, Rania A ^a   Asker, Mervat E ^a   Mohamed, Hoda E ^a  

^a Zagazig University   (Egypt)

Author keywords

cardiac fibrosis; cardiac hypertrophy; diabetic nephropathy; pioglitazone; transforming growth factor 1

Indexed keywords

COLLAGEN FIBER; CREATINE KINASE MB; GELATINASE A; PIOGLITAZONE; TISSUE INHIBITOR OF METALLOPROTEINASE 2; TRANSFORMING GROWTH FACTOR BETA1;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CREATINE KINASE BLOOD LEVEL; DIABETIC NEPHROPATHY; DRUG EFFECT; GENE EXPRESSION; HEART; HEART HYPERTROPHY; HEART MUSCLE CELL; HEART MUSCLE FIBROSIS; LIPID PEROXIDATION; MALE; NEPHRECTOMY; NONHUMAN; PRIORITY JOURNAL; RAT; STREPTOZOCIN DIABETES; UPREGULATION;

ANIMALS; BLOOD GLUCOSE; BLOOD PRESSURE; BODY WEIGHT; CREATININE; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC NEPHROPATHIES; FIBROSIS; GENE EXPRESSION REGULATION; HEART; HEART DISEASES; HYPOGLYCEMIC AGENTS; LIPID PEROXIDATION; LIPIDS; MALE; MYOCARDIUM; ORGAN SIZE; RANDOM ALLOCATION; RATS; RATS, WISTAR; THIAZOLIDINEDIONES;

EID: 84865112302     PISSN: 10742484     EISSN: 19404034     Source Type: Journal    
DOI: 10.1177/1074248411431581     Document Type: Article

References (44)

1. Wu T, McGrath KC, Death AK. Cardiovascular disease in diabetic nephropathy patients: cell adhesion molecules as potential markers?. Vasc Health Risk Manag. 2005 ; 1 (4). 309-316
2. Falcao-Pires I, Goncalves N, Moura C, et al. Effects of diabetes mellitus, pressure-overload and their association on myocardial structure and function. Am J Hypertens. 2009 ; 22 (11). 1190-1198
3. Brower GL, Gardner JD, Forman MF, et al. The relationship between myocardial extracellular matrix remodeling and ventricular function. Eur J Cardiothorac Surg. 2006 ; 30 (4). 604-610 (Pubitemid 44332949)
4. Spinale FG. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol Rev. 2007 ; 87 (4). 1285-1342 (Pubitemid 350041472)
5. Raffetto JD, Khalil RA. Matrix metalloproteinases and their inhibitors in vascular remodeling and vascular disease. Biochem Pharmacol. 2008 ; 75 (2). 346-359 (Pubitemid 350298459)
6. Hijova E. Matrix metalloproteinases: their biological functions and clinical implications. Bratisl Lek Listy. 2005 ; 106 (3). 127-132
7. Lu L, Zhang Q, Pu LJ, et al. Dysregulation of matrix metalloproteinases and their tissue inhibitors is related to abnormality of left ventricular geometry and function in streptozotocin-induced diabetic minipigs. Int J Exp Pathol. 2008 ; 89 (2). 125-137 (Pubitemid 351365192)
8. Asbun J, Villarreal FJ. The pathogenesis of myocardial fibrosis in the setting of diabetic cardiomyopathy. J Am Coll Cardiol. 2006 ; 47 (4). 693-700 (Pubitemid 43243087)
9. Yki-Jarvinen H. Thiazolidinediones. N Engl J Med. 2004 ; 351 (11). 1106-1118
10. Ajjan RA, Grant PJ. Cardiovascular disease prevention in patients with type 2 diabetes: the role of oral anti-diabetic agents. Diab Vasc Dis Res. 2006 ; 3 (3). 147-158 (Pubitemid 44902480)
11. Barnett AH. Redefining the role of thiazolidinediones in the management of type 2 diabetes. Vasc Health Risk Manag. 2009 ; 5 (1). 141-151
12. Yokozawa T, Nakagawa T, Wakaki K, Koizumi F. Animal model of diabetic nephropathy. Exp Toxicol Pathol. 2001 ; 53 (5). 359-363 (Pubitemid 33054901)
13. Polizio AH, Balestrasse KB, Yannarelli GG, et al. Angiotensin II regulates cardiac hypertrophy via oxidative stress but not antioxidant enzyme activities in experimental renovascular hypertension. Hypertens Res. 2008 ; 31 (2). 325-334 (Pubitemid 351461113)
14. Trinder P. Determination of blood glucose using an oxidase-peroxidase system with a non-carcinogenic chromogen. J Clin Pathol. 1969 ; 22 (2). 158-161
15. Gerhardt W, Waldenstrom J. Creatine kinase B-subunit activity in serum after immunoinhibition of M-subunit activity. Clin Chem. 1979 ; 25 (7). 1274-1280 (Pubitemid 9253240)
16. Husdan H, Rapoport A.. Estimation of creatinine by the Jaffe reaction. A comparison of three methods. Clin Chem. 1968 ; 14 (3). 222-238
17. Nakamoto M, Ohya Y, Shinzato T, et al. Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension. Hypertens Res. 2008 ; 31 (2). 353-361 (Pubitemid 351461116)
18. Ohkawa H, Ohishi N, Yagi K. Assay for lipid peroxides in animal tissues by thiobarbituric acid reaction. Anal Biochem. 1979 ; 95 (2). 351-358 (Pubitemid 9194347)
19. Aso Y. Cardiovascular disease in patients with diabetic nephropathy. Curr Mol Med. 2008 ; 8 (6). 533-543
20. Rojas A, Mercadal E, Figueroa H, Morales MA. Advanced glycation and ROS: a link between diabetes and heart failure. Curr Vasc Pharmacol. 2008 ; 6 (1). 44-51
21. Fiordaliso F, Bianchi R, Staszewsky L, et al. Antioxidant treatment attenuates hyperglycemia-induced cardiomyocyte death in rats. J Mol Cell Cardiol. 2004 ; 37 (5). 959-968 (Pubitemid 39446821)
22. Shirpoor A, Salami S, Khadem-Ansari MH, et al. Cardioprotective effect of vitamin E: rescues of diabetes-induced cardiac malfunction, oxidative stress, and apoptosis in rat. J Diabetes Complications. 2009 ; 23 (5). 310-316
23. Wei W, Liu Q, Tan Y, Liu L, Li X, Cai L. Oxidative stress, diabetes, and diabetic complications. Hemoglobin. 2009 ; 33 (5). 370-377
24. Singh VP, Baker KM, Kumar R. Activation of the intracellular renin-angiotensin system in cardiac fibroblasts by high glucose: role in extracellular matrix production. Am J Physiol Heart Circ Physiol. 2008 ; 294 (4). H1675 - H1684
25. Aragno M, Mastrocola R, Alloatti G, et al. Oxidative stress triggers cardiac fibrosis in the heart of diabetic rats. Endocrinology. 2008 ; 149 (1). 380-388
26. Cohn JN, Ferrari R, Sharpe N. Cardiac remodeling-concepts and clinical implications: a consensus paper from an international forum on cardiac remodeling. Behalf of an international forum on cardiac remodeling. J Am Coll Cardiol. 2000 ; 35 (3). 569-582 (Pubitemid 30167013)
27. Porter KE, Turner NA. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol Ther. 2009 ; 123 (2). 255-278
28. Simko F. Physiologic and pathologic myocardial hypertrophy-physiologic and pathologic regression of hypertrophy?. Med Hypotheses. 2002 ; 58 (1). 11-14 (Pubitemid 34136721)
29. Singh VP, Le B, Khode R, Baker KM, Kumar R. Intracellular angiotensin II production in diabetic rats is correlated with cardiomyocyte apoptosis, oxidative stress, and cardiac fibrosis. Diabetes. 2008 ; 57 (12). 3297-3306
30. Wang B, Omar A, Angelovska T, et al. Regulation of collagen synthesis by inhibitory Smad7 in cardiac myofibroblasts. Am J Physiol Heart Circ Physiol. 2007 ; 293 (2). H1282 - H1290
31. Van Linthout S, Seeland U, Riad A, et al. Reduced MMP-2 activity contributes to cardiac fibrosis in experimental diabetic cardiomyopathy. Basic Res Cardiol. 2008 ; 103 (4). 319-327
32. Visse R, Nagase H. Matrix metalloproteinases and tissue inhibitors of metalloproteinases: structure, function, and biochemistry. Circ Res. 2003 ; 92 (8). 827-839 (Pubitemid 36542523)
33. Lovelock JD, Baker AH, Gao F, et al. Heterogeneous effects of tissue inhibitors of matrix metalloproteinases on cardiac fibroblasts. Am J Physiol Heart Circ Physiol. 2005 ; 288 (2). H461 - H468
34. Li Q, Sun SZ, Wang Y, Tian YJ, Liu MH. The roles of MMP-2/TIMP-2 in extracellular matrix remodelling in the hearts of STZ-induced diabetic rats. Acta Cardiol. 2007 ; 62 (5). 485-491 (Pubitemid 47582641)
35. Elte JW, Blickle JF. Thiazolidinediones for the treatment of type 2 diabetes. Eur J Intern Med. 2007 ; 18 (1). 18-25 (Pubitemid 46072729)
36. Toba H, Miki S, Shimizu T, et al. The direct antioxidative and anti-inflammatory effects of peroxisome proliferator-activated receptors ligands are associated with the inhibition of angiotensin converting enzyme expression in streptozotocin-induced diabetic rat aorta. Eur J Pharmacol. 2006 ; 549 (1-3). 124-132 (Pubitemid 44441265)
37. Gumieniczek A. Effects of pioglitazone on hyperglycemia-induced alterations in antioxidative system in tissues of alloxan-treated diabetic animals. Exp Toxicol Pathol. 2005 ; 56 (4-5). 321-326 (Pubitemid 40312757)
38. Nakamura T, Yamamoto E, Kataoka K, et al. Beneficial effects of pioglitazone on hypertensive cardiovascular injury are enhanced by combination with candesartan. Hypertension. 2008 ; 51 (2). 296-301 (Pubitemid 351159942)
39. Fukuda M, Nakamura T, Kataoka K, et al. Potentiation by candesartan of protective effects of pioglitazone against type 2 diabetic cardiovascular and renal complications in obese mice. J Hypertens. 2010 ; 28 (2). 340-352
40. Chen K, Chen J, Li D, Zhang X, Mehta JL. Angiotensin II regulation of collagen type I expression in cardiac fibroblasts: modulation by PPAR-gamma ligand pioglitazone. Hypertension. 2004 ; 44 (5). 655-661 (Pubitemid 39435235)
41. Duan SZ, Ivashchenko CY, Russell MW, Milstone DS, Mortensen RM. Cardiomyocyte-specific knockout and agonist of peroxisome proliferator-activated receptor-gamma both induce cardiac hypertrophy in mice. Circ Res. 2005 ; 97 (4). 372-379 (Pubitemid 41216142)
42. Shiomi T, Tsutsui H, Hayashidani S, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation. 2002 ; 106 (24). 3126-3132 (Pubitemid 35440299)
43. Poornima IG, Parikh P, Shannon RP. Diabetic cardiomyopathy: the search for a unifying hypothesis. Circ Res. 2006 ; 98 (5). 596-605
44. Lee HH, Yeh CH, Chen YT, et al. Effects of metformin on rosiglitazone-induced cardiac hypertrophy in mice. Biol Pharm Bull. 2010 ; 33 (9). 1506-1510